New cancer drug trial seeks to control advanced tumors
NCT ID NCT05423262
Summary
This early-stage study is testing a new drug called TRK-950 in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: testing TRK-950 alone, testing it combined with an existing immunotherapy (nivolumab), and specifically testing it in advanced melanoma patients. The main goals are to find safe doses and see if the drug helps control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Keio University Hospital
RECRUITINGShinjuku-Ku, Tokyo, 160-8582, Japan
Contact
-
Kumamoto University Hospital
RECRUITINGKumamoto, Kumamoto, 860-8556, Japan
Contact
-
Nagoya City University Hospital
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
Contact
-
National Cancer Center Hospital
RECRUITINGChuo Ku, Tokyo, 104-0045, Japan
Contact
-
National Hospital Organization Kyushu Cancer Center
RECRUITINGFukuoka, Fukuoka, 811-1395, Japan
Contact
-
Niigata Cancer Center Hospital
RECRUITINGNiigata, Niigata, 951-8566, Japan
Contact
-
Saitama Medical University International Medical Center
RECRUITINGHidaka, Saitama, 350-1298, Japan
Contact
-
Sapporo Medical University Hospital
RECRUITINGSapporo, Hokkaido, 060-8543, Japan
Contact
-
Shinshu University Hospital
RECRUITINGMatsumoto, Nagano, 390-8621, Japan
Contact
Conditions
Explore the condition pages connected to this study.